As new technologies emerge, numerous biotech startups are launched across Europe every year. With specialised venture capital firms and technology companies pouring money into the sector, biotech startups now attract a record amount of investment. Most of these investments focus on predicting which drugs will work and be safe for humans, well before the testing process begins. In the case of diseases such as Alzheimer’s, current animal models do not ensure effective evaluation of whether a drug will work in humans. But with today’s biotech offerings in the market, scientists are able to convert any human cell into a stem cell to create custom’ disease in a dish’ models for enhanced predictability.
By leveraging modern technologies, biotech startups have also significantly reduced the expenditure of reading the entire sequence of a person’s genome. With cost-effective genome sequencing, researchers are now able to screen the DNA of patients to find genetic biomarkers and in turn, select the most suitable treatment for a person based on their genetics. Building on this trend, technologies such as organoids, organs-on-chips, and 3D bioprinting are helping mimic the real behaviour of human tissues in the lab, thus improving the entire testing process.
As biotech startups continue to evolve by embracing new technologies, organisations must opt for solutions and services most relevant to their business requirements. To assist them with the same, our distinguished panel comprising key decision makers and experts along with StartupCity’s editorial board has shortlisted some of the most promising biotech startups in Europe.
We present to you StartupCity’s “15 Most Promising BioTech Startups in Europe - 2019.”
